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The following Cancer and Leukemia Group B (CALGB)/Alliance for Clinical Trials in 
Oncology (Alliance) institutional networks participated in this study and contributed at 
least five patients. For each of these institutions, the current or last principal investigator 
is listed as follows: 
 
The Ohio State University Medical Center, Columbus, OH, Claire F. Verschraegen; 
Roswell Park Comprehensive Cancer Center, Buffalo, NY; Ellis G. Levine; Wake Forest 
University School of Medicine, Winston-Salem, NC; Heidi D. Klepin; Northwell Health 
NCORP, Lake Success, NY, Jonathan E. Kolitz; University of Chicago Comprehensive 
Cancer Center, Chicago, IL, Hedy L. Kindler; University of Iowa/Holden Comprehensive 
Cancer Center, Iowa City, IA, Umar Farooq; Medical University of South Carolina, 
Charleston, SC, Scott M. Lindhorst; Washington University School of Medicine, St. Louis, 
MO, Nancy L. Bartlett; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 
Matthew I. Milowsky; University of Vermont and State Agricultural College, Burlington, 
VT, Peter A. Kaufman; Dana-Farber/Partners CancerCare, Boston, MA, Harold J. 
Burstein; Florida Hospital Cancer Institute CCOP, Orlando, FL, Carlos Alemany; Ft. 
Wayne Medical Oncology/Hematology, Ft. Wayne, IN, Sreenivasa Nattam; University of 
Maryland/Greenebaum Cancer Center, Baltimore, MD, Heather D. Mannuel; Western 
Pennsylvania Hospital, Pittsburgh, PA: Gene G. Finley; Mission Hospitals Inc., Asheville, 
NC, Cameron B. Harkness; Dartmouth College -Norris Cotton Cancer Center, Lebanon, 
NH, Konstantin H. Dragnev; Duke University – Duke Cancer Institute, Durham, NC, 
Jeffrey Crawford; Waukesha Memorial Hospital, Waukesha, WI, Timothy R. Wassenaar; 
Rhode Island Hospital, Providence, RI, Howard P. Safran; Georgetown University 
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Medical Center, Washington, DC, Minnetta C. Liu; NCORP of the Carolinas (Greenville 
Health System NCORP), Greenville, SC; Ki Y. Chung; Stony Brook University Medical 
Center, Stony Brook, NY; Michael M. Schuster; Via Christi Regional Medical Center, 
Wichita, KS, Shaker R. Dakhil; Eastern Maine Medical Center, Bangor, ME, Sarah J. 
Sinclair; Delaware/Christiana Care NCI Community Oncology Research Program, 
Newark, DE, Gregory A. Masters; Massachusetts General Hospital, Boston, MA, David 
Ryan and Justin Gainor; University of Minnesota/Masonic Cancer Center, Minneapolis, 
MN, Anne H. Blaes; Phoebe Putney Memorial Hospital, Albany, GA, Chirag R. Jani, 
Heartland Cancer Research NCORP, Decatur, IL, Bryan Faller; Missouri Cancer 
Associates, Columbia, MO, Mount Sinai Medical Center, Miami Beach, FL, Michael 
Swartz; National Capital Area Minority Underserved NCORP, Washington, DC, Marcus 
Noel; Nevada Cancer Research Foundation NCORP, Las Vegas, NV, John Ellerton; 
Northern Indiana Cancer Research Consortium, South Bend, IN; State University of New 
York Upstate Medical University, Syracuse, NY, Stephen Graziano; UC San Diego 
Moores Cancer Center, La Jolla, CA, Lyudmila Bazhenova; University of Missouri-Ellis 
Fischel, Columbia, MO, Puja Nistala; University of Nebraska Medical Center, Omaha, NE, 
Apar Ganti; and University of Oklahoma Health Sciences Center LAPS, Oklahoma City, 
OK, Adam Asch. 
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Supplemental Tables and Figures 
 
 
Supplemental Table 1. Intent to treat response and survival by age group 
 
End point ≥70 years <70 years 
 Arm A: G3139 Arm B: control P Arm A: G3139 Arm B: control P 
Complete remission   .008   .52 












Overall survival   .55   .04 


































Event-free survival   .33   .19 


































Disease-free survival   .80   .16 
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Supplemental Table 2. Intent to treat response and survival by AML type 
 
End point AML de novo Secondary AML 
 Arm A: G3139 Arm B: control P Arm A: G3139 Arm B: control P 
Complete remission   .76   .68 












Overall survival   .56   .15 


































Event-free survival   .81   .78 


































Disease-free survival   .69   .04 
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Supplemental Table 3. Specific transplant type for patients who received hematopoietic cell 
transplantation 
 
Transplant type Arm A: G3139 (n=24) 




BM from matched sibling, n (%) 4 (16.7) 5 (22.7) 9 (19.6) 
PBSC from matched sibling, n (%) 10 (41.7) 6 (27.3) 16 (34.8) 
BM from matched unrelated donor, n (%) 1 (4.2) 3 (13.6) 4 (8.7) 
PBSC from matched unrelated donor, n (%) 2 (8.3) 5 (22.7) 7 (15.2) 
Autologous BM, n (%) 2 (8.3) 1 (4.5) 3 (6.5) 
Autologous PBSC, n (%) 3 (12.5) 1 (4.5) 4 (8.7) 
Other, n (%) 2 (8.3) 1 (4.5) 3 (6.5) 
 
BM, bone marrow; PBSC, peripheral blood stem cells. 
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71 received consolidation cycle 2 
0 Had disease progression 
72 received consolidation cycle 2 
2 Had disease progression 
252 Were assigned to Arm B 
246 Received assigned intervention 
6 did not receive intervention 
254 Were assigned to Arm A 
249 Received assigned intervention 
5 did not receive intervention 
506 patients underwent 
randomization 
249 entered induction phase 
13 Had disease progression 
29 Died 
12 Withdrew 
8 Underwent alternative therapy 
2 Had other disease 
16 Had other reasons 
16 Had toxicity/side effects/complications 
246 entered induction phase 
9 Had disease progression 
30 Died 
11 Withdrew 
5 Underwent alternative therapy 
3 Had other disease 
19 Had other reasons 
13 Had toxicity/side effects/complications 
64 received a second cycle of 
induction therapy 
3 Had disease progression 
7 Died 
1 Withdrew 
0 Underwent alternative therapy 
5 Had toxicity/side effects/complications 
66 received a second cycle of induction 
therapy 
2 Had disease progression 
5 Died 
2 Withdrew 
2 Underwent alternative therapy 
2 Had toxicity/side effects/complications 
102 received consolidation cycle 1 
9 Had disease progression 
3 Died 
3 Withdrew 
2 underwent alternative therapy 
9 Had toxicity/side effects/complications 
108 received consolidation cycle 1 
12 Had disease progression 
3 Died 
6 Withdrew 
1 Underwent alternative therapy 
5 Had toxicity/side effects/complications 
24 Underwent transplantation 
5 autologous transplants 
19 allogeneic transplants 
22 Underwent transplantation 
2 autologous transplants 
20 allogeneic transplants 
254 included in the intention to treat 
analysis 




Supplemental Figure 1. Screening, Randomization, and Treatment. Eleven patients were 
registered in the trial and underwent randomization, but did not receive the trial treatment. 
In accordance with the rule for intention-to-treat, these patients were included in the 





Supplemental Figure 2. Overall survival of AML patients who underwent allogeneic 





Supplemental Figure 2. Kaplan-Meier curves for overall survival in the G3139 group and the 
control group, among patients who underwent allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 3. Event-free survival of AML patients who underwent allogeneic 





Supplemental Figure 3. Kaplan-Meier curves for event-free survival in the G3139 group and 
the control group, among patients who underwent allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 4. Disease-free survival of AML patients who underwent allogeneic 





Supplemental Figure 4. Kaplan-Meier curves for disease-free survival in the G3139 group and 
the control group, among patients who underwent allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 5. Overall survival of AML patients, censoring at the time of 




Supplemental Figure 5. Kaplan-Meier curves for overall survival (OS) in the G3139 group and the control 
group. OS was censored at the time of allogeneic hematopoietic cell transplantation. CI=Confidence 
Interval. Median survival in months. 
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Supplemental Figure 6. Event-free survival of AML patients, censoring at the time of 





Supplemental Figure 6. Kaplan-Meier curves for event-free survival (EFS) in the G3139 group 
and the control group. EFS was censored at the time of allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 7. Disease-free survival of AML patients, censoring at the 





Supplemental Figure 7. Kaplan-Meier curves for disease-free survival (DFS) in the G3139 
group and the control group. DFS was censored at the time of allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 8. Overall survival of AML patients who did not undergo 





Supplemental Figure 8. Kaplan-Meier curves for overall survival in the G3139 group and the control group, 
among patients who did not undergo allogeneic hematopoietic cell transplantation. CI=Confidence 
Interval. Median survival in months. 
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Supplemental Figure 9. Event-free survival of AML patients who did not undergo 





Supplemental Figure 9. Kaplan-Meier curves for event-free survival in the G3139 group and 
the control group, among patients who did not undergo allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 10. Disease-free survival of AML patients who did not undergo 







Supplemental Figure 10. Kaplan-Meier curves for disease-free survival in the G3139 group 
and the control group, among patients who did not undergo allogeneic hematopoietic cell 
transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 11. Overall survival of patients with secondary AML who did not 







Supplemental Figure 11. Kaplan-Meier curves for overall survival in the G3139 group and the 
control group, among secondary AML patients who did not undergo allogeneic hematopoietic 
cell transplantation. CI=Confidence Interval. Median survival in months. 
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Supplemental Figure 12. Disease-free survival of patients with secondary AML who did 





Supplemental Figure 12. Kaplan-Meier curves for disease-free survival in the G3139 group 
and the control group, among secondary AML patients who did not undergo allogeneic 
hematopoietic cell transplantation. CI=Confidence Interval. Median survival in months. 
